Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy

Engagement advances clinical execution of IBC101, Liminatus’ CD19xCD22 bivalent CAR-T therapy for relapsed or refractory B-cell malignancies

FULLERTON, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biotechnology company developing innovative cancer therapies, today announced that it has engaged Synex Consulting Ltd. (“Synex”), a Korea-based full-service contract research organization (“CRO”), to support the clinical development of IBC101, the Company’s CD19xCD22 bivalent CAR-T cell therapy candidate.

The engagement represents an important step in advancing IBC101 toward clinical execution in South Korea. IBC101 has received authorization from the Ministry of Food and Drug Safety of the Republic of Korea (MFDS) for a Phase 1/2a clinical study in patients with relapsed or refractory diffuse large B-cell lymphoma (“DLBCL”), with Seoul St. Mary’s Hospital identified as the lead clinical site.

Under the engagement, Synex will provide clinical research services pursuant to a milestone-based program, with payments linked to key clinical development milestones, including patient enrollment, database lock and completion of the clinical study report.

“Engaging Synex is another important step in moving IBC101 from regulatory authorization toward clinical execution,” said Chris Kim, Chief Executive Officer of Liminatus. “Synex brings extensive experience supporting pharmaceutical clinical development in Korea, and we believe its local regulatory and clinical capabilities will be valuable as we advance the IBC101 Phase 1/2a program.”

IBC101 is an autologous CD19xCD22 bivalent CAR-T cell therapy designed for relapsed or refractory B-cell malignancies. The candidate utilizes an OR-gate approach intended to recognize malignant B cells expressing either CD19 or CD22. By targeting two established B-cell antigens, IBC101 is designed to broaden antigen coverage and potentially address antigen escape and tumor heterogeneity, two mechanisms associated with relapse following single-antigen CAR-T therapy.

The IBC101 program further expands Liminatus’ oncology development portfolio beyond its IBA101 CD47 checkpoint inhibitor program and establishes an additional clinical-stage development pathway focused on hematologic malignancies.

“Following the expansion of our oncology portfolio, our focus is increasingly shifting toward execution across our development programs,” added Mr. Kim. “The Synex engagement provides clinical infrastructure in Korea to support the next stage of IBC101’s development, and we look forward to progressing the program toward patient enrollment.”

About IBC101

IBC101 is an investigational autologous CD19xCD22 bivalent CAR-T cell therapy candidate designed for the treatment of relapsed or refractory B-cell malignancies. The therapy is designed as an OR-gate CAR-T system capable of recognizing tumor cells expressing either CD19 or CD22, with the goal of expanding antigen coverage and reducing the potential for antigen escape associated with single-target CAR-T therapies. IBC101 has received authorization from the MFDS for a Phase 1/2a clinical study in relapsed or refractory DLBCL.

About Liminatus Pharma, Inc.

Liminatus Pharma, Inc. (Nasdaq: LIMN) is a biotechnology company developing innovative immuno-oncology and cell therapy candidates. The Company’s portfolio includes IBA101, a next-generation anti-CD47 monoclonal antibody, as well as oncology-focused cellular therapy programs including IBC101, a CD19xCD22 bivalent CAR-T candidate for B-cell malignancies. Liminatus is focused on advancing differentiated therapeutic approaches designed to address significant unmet needs in cancer treatment.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of applicable federal securities laws. Forward-looking statements include statements regarding the clinical development of IBC101, the timing and initiation of clinical trial activities, patient enrollment, the expected services to be provided by Synex, the potential therapeutic benefits of IBC101, and the Company’s plans for its development programs. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding risks and uncertainties affecting Liminatus is contained in the Company’s filings with the Securities and Exchange Commission. Liminatus undertakes no obligation to update any forward-looking statements except as required by applicable law.

Investor Contact:
Liminatus Pharma, Inc.

Chris Kim, CEO info@liminatuspharma.com (213) 273-5453